Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148798
Status:
COMPLETED
Last Update Posted:
2014-06-25
First Post:
2005-09-07
Brief Title:
Study of CisplatinVinorelbine - Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer FLEX
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
EMR 62202-046
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None